Is there a role for maintenance therapy after platinum chemotherapy in bladder cancer in the era of immune therapy?

Future Oncol. 2019 Dec;15(34):3877-3879. doi: 10.2217/fon-2019-0542. Epub 2019 Nov 15.

Authors

Elie Rassy¹, Tarek Assi¹, Joseph Kattan¹

Affiliation

¹ Department of Oncology, Saint Joseph University, Faculty of Medicine, Beirut, Lebanon.

PMID: 31729240
DOI: 10.2217/fon-2019-0542

No abstract available

Keywords: bladder; immune checkpoint inhibitors; immunotherapy; maintenance; urothelial.

Publication types

Editorial

MeSH terms

Antineoplastic Agents, Immunological / therapeutic use
B7-H1 Antigen / antagonists & inhibitors
B7-H1 Antigen / immunology
B7-H1 Antigen / metabolism
Carcinoma, Transitional Cell / drug therapy*
Carcinoma, Transitional Cell / immunology
Carcinoma, Transitional Cell / pathology
Cisplatin / therapeutic use
Disease Progression
Humans
Immunotherapy / methods*
Immunotherapy / trends
Maintenance Chemotherapy / methods*
Maintenance Chemotherapy / trends
Neoplasm Recurrence, Local / pathology
Neoplasm Recurrence, Local / prevention & control*
Randomized Controlled Trials as Topic
Treatment Outcome
Urinary Bladder / immunology
Urinary Bladder / pathology
Urinary Bladder Neoplasms / drug therapy*
Urinary Bladder Neoplasms / immunology
Urinary Bladder Neoplasms / pathology
Urothelium / immunology
Urothelium / pathology

Substances

Antineoplastic Agents, Immunological
B7-H1 Antigen
CD274 protein, human
Cisplatin